Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration...
-
Egnyte has a built-in, GxP-validated eSignature solution, 21 CFR Part 11 compliant & controlled docs have configurable categories & document statuses.
-
Soficitinib demonstrated a favorable safety profile and encouraging efficacy in treating patients with moderate-to-severe AD.
-
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...
-
MONTRÉAL, 28 janv. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la «Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement intégré...
-
Cannara receives conditional approval to uplist from the TSXV to the TSX, enhancing visibility and liquidity as it completes final listing requirements.
-
Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology
-
Acquisition adds further specialist biostatistics, data management, and medical writing expertise to Evestia Clinical’s full-service offering and strengthens its presence in Germany and across Europe ...
-
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
-
EPIDAREX CAPITAL ANNOUNCES FIRST CLOSE OF FUND IV, SECURING $145 MILLION TO BUILD NEXT WAVE OF LIFE SCIENCE START-UPS New Fund will target company creation and early-stage investing across the UK and...